Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease

Juan José Segura-Sampedro¹*, Rafael Morales-Soriano², Álvaro Arjona-Sánchez³ and Pedro Cascales-Campos⁴

Abstract
Recent evidence suggested that secondary surgical cytoreduction followed by chemotherapy does not result in longer overall survival in patients with platinum-sensitive recurrent ovarian cancer. This statement is based on a phase III multicenter, randomized clinical trial that lacks a description of the surgical protocol, the surgical technique, and the surgical variables. In a study that evaluates surgical cytoreduction, it is mandatory to assess the grade of cytoreductive surgery achieved (Sugarbaker PH, Langenbeck's Arch Surg 384:576–87, 1999), the extent of disease using PCI (Peritoneal Cancer Index), the technique itself, and the existence of a multidisciplinary approach with extensive upper abdominal procedures in experienced centers (Ren et al, BMC Cancer 15:1-12, 2015). There is evidence proving that the quality of cytoreduction (Al Rawahi et al, Cochrane Database Syst Rev 2013, 2013), the measurement of the amount of disease by PCI (Elzarkaa et al, J Gynecol Oncol 29, 2018), and a multidisciplinary approach with supramesocolic procedures (Ren et al, BMC Cancer 15:1-12, 2015) impact overall survival. This study fails to compare chemotherapy with secondary cytoreductive surgery since, due to the lack of variables, we can assess neither the performed surgery nor its criteria. This study should not be taken into account to recommend chemotherapy alone over a surgical approach in this group of patients.

Keywords: Ovarian cancer, HIPEC, Chemotherapy, Cytoreductive surgery, Carcinomatosis

Dear Editor,
We have read with great interest the paper by Coleman et al. [1] which states that “patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone.”

The use of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer with peritoneal dissemination is currently experiencing expansion [2]. Recently, a phase III study [3] indicated advantageous results for HIPEC after cytoreduction versus cytoreduction alone in patients treated with HIPEC after neoadjuvant chemotherapy (NACT). Furthermore, interval cytoreductive surgery plus HIPEC proved to be a cost-effective management of stage III epithelial ovarian cancer (EOC) when NACT was administered; consequently, some societies have acknowledged the applicability of HIPEC in such clinical situations [4].

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
We congratulate the researchers involved in this open-label, phase III multicenter, international, industry-funded, randomized clinical trial for assessing the benefits of secondary surgical cytoreduction in platinum-sensitive surgically amenable patients.

The aim of the GOG-0213 trial was double. First, to prove that bevacizumab (drug produced by the funder of the study) improves overall survival (OS) when added to paclitaxel and carboplatin chemotherapy followed by maintenance bevacizumab. Second, to prove that secondary surgical cytoreduction in platinum-sensitive surgically amenable patients improves OS compared to the proposed chemotherapy protocol.

Four hundred eighty-five patients were randomly assigned to control arm (surveillance with no surgery, \( n = 245 \); 15 declined surgery, 221 were finally operated). 240 followed this strategy, 5 patients received surgery performed by all the teams fulfilled these criteria; therefore, OS is biased again at this point. Although “more than half the patients had two or fewer sites of recurrent disease,” only 68% had a “complete cytoreductive surgery.” These results are somehow inconsistent and may reflect the above-mentioned points: lack of a multidisciplinary approach, no supramesocolic protocol, absence of PCI evaluation, no score for completeness of cytoreduction, and lack of high-volume centers.

To conclude, this study proved that the addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer [14]. Nevertheless, it has failed to compare this chemotherapy protocol with secondary cytoreductive surgery since, due to the lack of variables, we can assess neither the performed surgery nor its criteria. The results of this study should not be taken into account to recommend chemotherapy alone over a surgical approach in this group of patients.

Acknowledgements

No.

Author disclosures

Drs. JS, RM, AA, PC has nothing to disclose.

Authors’ contributions

JS and RM wrote the manuscript. AA and PC made the critical review and added new considerations. The authors read and approved the final manuscript.

Funding

No funding was required for this manuscript.

Availability of data and materials

There is no other data to be shared.

Ethics approval and consent to participate

This manuscript does not include human participants, human data, or human tissue.

Consent for publication

This manuscript does not contain individual person’s data.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of General and Digestive Surgery, Son Espases University Hospital, Spain, 07010 Palma de Mallorca, Spain. Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. School of Medicine, University of the Balearic Islands (UIB), Palma de Mallorca, Spain. 2Department of General and Digestive Surgery, Son Espases University Hospital, Spain, 07010 Palma de Mallorca, Spain. Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. 3General & Digestive Surgery Department, University Hospital Reina Sofia, School of Medicine,
References

1. Coleman RL, Spiritos NM, Ensero D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929–39 https://doi.org/10.1056/NEJMoa1902626.

2. Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of cytoreductive surgery plus hyperthermic intraoperative chemotherapy (HIPEC) versus cytoreductive surgery for ovarian cancer patients: a systematic review and meta-analysis. Eur J Surg Oncol. 2019;45:301–9 https://doi.org/10.1016/j.ejso.2018.10.528.

3. Van Driel WJ, Koole SN, Sikorska K, SchagenvanLeeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40 https://doi.org/10.1056/NEJMoa1708618.

4. Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019;153:376–80 https://doi.org/10.1016/j.ygyno.2019.01.025.

5. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384:576–87 https://doi.org/10.1007/s004230050246.

6. Angarita AM, Stone R, Temkin SM, Levinson K, Fader AN, Tanner EJ. The use of “optimal cytoreduction” nomenclature in ovarian cancer literature. Int J Gynecol Cancer. 2016;26:1421–7 https://doi.org/10.1097/IGC.0000000000000796.

7. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2013 https://doi.org/10.1002/14651858.CD008765.pub3.

8. Altmann AD, Nelson G, Chu P, Nation J, Ghatage P. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. J Obstet Gynaecol Can. 2012;34:558–566. https://doi.org/10.1016/S1701-2163(16)35272-0.

9. Gurkan D, Ceren Akin A, Sahin H, Aytaç Tohma Y, Sahin EA, Gunakan E, et al. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas. J Obstet Gynaecol (Lahore) 2019;9:1–7. https://doi.org/10.1080/01443615.2019.1634028.

10. Segura-Sampedro JJ, Morales-Soriano R, Sugarbaker PH. Indicadores Pronósticos, Incluyendo la Laparoscopia Diagnóstica. In: Cascales-Campos P, editor. Citorreducción y quimioterapia perioperatoria en las neoplasias malignas de la superficie peritoneal. Arán Ediciones, 2018, p. 1–16.

11. Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Mels M, Malik E, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29 https://doi.org/10.3802/jgo.2018.29.e47.

12. Eng OS, Raof M, Blakely AM, Yu X, Lee SJ, Han ES, et al. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer. J Surg Oncol. 2018;118:121–6 https://doi.org/10.1002/jso.25120.

13. Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIC and IV ovarian cancer: an observational study. BMC Cancer. 2015;15:1–12 https://doi.org/10.1186/s12885-015-1525-1.

14. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (INRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779–791. https://doi.org/10.1016/S1470-2045(17)30279-6.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions